Revenue-- Revenue net of returns was $86,000, reflecting intentional reductions in ClearUp marketing and unit sales. Operating expenses-- Operating expenses were $2.0 million, up from $1.3 million in ...

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains ...